Skip to content
Sign in

BCYC · NASDAQ

Bicycle Therapeutics (BCYC) Stock Price & Fundamentals

$623.25−1.47%−$9.32End-of-day price as of Oct 9, 2026

Bicycle Therapeutics (BCYC) closed at $623.25 on Oct 9, 2026, down 1.47% from the previous close of $632.57.

Share price, past year

1Y +40.11%

52-week range $435.01 – $634.07. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$623.25
Sep 30, 2026$625.44
Aug 31, 2026$591.38
Jul 31, 2026$585.43
Jun 30, 2026$552.31
May 29, 2026$527.16
Apr 30, 2026$493.87
Mar 31, 2026$492.55
Feb 27, 2026$476.09
Jan 30, 2026$475.90
Dec 31, 2025$446.44
Nov 28, 2025$450.33
Oct 31, 2025$458.57

Key statistics

Market cap
$43.51B
P/E (TTM)
—
EPS (TTM)
−$2.73
Revenue (TTM)
$61.21M
Net income (TTM)
−$190.41M
Shares outstanding
69.8M
Dividend yield
—
52-week range
$435.01 – $634.07

Bicycle Therapeutics's market cap is $43.51B, based on a share price of $623.25 and 69.8M shares outstanding as of Jun 30, 2026.

Financials

Bicycle Therapeutics reported revenue of $72.59M for fiscal 2025, up 105.77% from fiscal 2024.

Bicycle Therapeutics reported a net loss of $218.96M in fiscal 2025.

Fiscal 2025 revenue was the highest in the 9 years shown.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Bicycle Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$72.59M+105.8%−$218.96M−301.7%−$3.16−$252.03M
FY2024ended Dec 31, 2024$35.28M+30.8%−$169.03M−479.2%−$2.90−$165.96M
FY2023ended Dec 31, 2023$26.98M+86.5%−$180.66M−669.7%−$5.08−$63.56M
FY2022ended Dec 31, 2022$14.46M+23.7%−$112.72M−779.4%−$3.80−$105.10M
FY2021ended Dec 31, 2021$11.70M+12.6%−$66.82M−571.3%−$2.67−$16.82M
FY2020ended Dec 31, 2020$10.39M−24.7%−$51.01M−491.0%−$2.66−$18.99M
FY2019ended Dec 31, 2019$13.80M+93.4%−$30.61M−221.8%−$2.77−$30.17M
FY2018ended Dec 31, 2018$7.14M+246.4%−$21.85M−306.1%−$49.78−$27.26M
FY2017ended Dec 31, 2017$2.06M—−$16.26M−789.3%−$48.81−$2.53M
Bicycle Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$629.00K−$50.33M−$0.72
Q1 FY2026ended Mar 31, 2026$887.00K−$60.83M−$0.87
Q4 FY2025ended Dec 31, 2025$47.96M−$20.15M−$0.29
Q3 FY2025ended Sep 30, 2025$11.73M−$59.10M−$0.85
Q2 FY2025ended Jun 30, 2025$2.92M−$78.95M−$1.14
Q1 FY2025ended Mar 31, 2025$9.98M−$60.75M−$0.88
Q4 FY2024ended Dec 31, 2024$3.71M−$51.85M−$0.77
Q3 FY2024ended Sep 30, 2024$2.68M−$50.80M−$0.74

Company profile

Name
Bicycle Therapeutics plc
Ticker
BCYC
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
Blocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, X0 CB21 6GS
Incorporated in
X0
Fiscal year ends
December
SEC CIK
0001761612

Recent SEC filings

Frequently asked questions

What is Bicycle Therapeutics's stock price?

Bicycle Therapeutics (BCYC) closed at $623.25 on Oct 9, 2026, down 1.47% from the previous close of $632.57.

What is Bicycle Therapeutics's market cap?

Bicycle Therapeutics's market cap is $43.51B, based on a share price of $623.25 and 69.8M shares outstanding as of Jun 30, 2026.

How much revenue does Bicycle Therapeutics make?

Bicycle Therapeutics reported revenue of $72.59M for fiscal 2025, up 105.77% from fiscal 2024.

Does Bicycle Therapeutics pay a dividend?

Yes. Bicycle Therapeutics declared $0.00 per share in dividends for fiscal 2025.

Sources and methodology

Fundamentals come from Bicycle Therapeutics plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures